Jonathan Young Sells 50,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 50,000 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $44.86, for a total transaction of $2,243,000.00. Following the transaction, the chief operating officer now directly owns 201,147 shares of the company’s stock, valued at approximately $9,023,454.42. This trade represents a 19.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jonathan Young also recently made the following trade(s):

• On Monday, February 3rd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.81, for a total transaction of $538,100.00.
• On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00.
• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total transaction of $77,067.37.

Akero Therapeutics Trading Down 3.2 %

Shares of AKRO opened at $43.67 on Friday. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average is $40.21 and its two-hundred day moving average is $33.07. The stock has a market cap of $3.05 billion, a PE ratio of -11.65 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Research analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AKRO. HC Wainwright lifted their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a report on Monday. Morgan Stanley lifted their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. UBS Group boosted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Citigroup boosted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Finally, Canaccord Genuity Group boosted their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics has an average rating of “Buy” and an average price target of $76.29.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its stake in Akero Therapeutics by 54.4% during the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after acquiring an additional 201,225 shares during the last quarter. RTW Investments LP boosted its position in shares of Akero Therapeutics by 15.9% during the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock valued at $190,840,000 after acquiring an additional 940,388 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Akero Therapeutics by 13.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,321,972 shares of the company’s stock valued at $120,238,000 after acquiring an additional 513,613 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Akero Therapeutics by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 3,704,411 shares of the company’s stock valued at $103,057,000 after acquiring an additional 27,830 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.